JAMA Network Home
Sign In
Viewpoint

Most-Favored-Nation Drug Pricing—How Courts Could Shape Future Health Regulation

JAMA Health Forum 10.1001/jamahealthforum.2025.5440

October 10, 2025 at 11:05 AM EDT

Read the full article

This Viewpoint discusses legal questions around the Trump administration’s recent Executive Order about most-favored-nation drug pricing in the US.

Corresponding Author: Benedic Ippolito, PhD, American Enterprise Institute, 1789 Massachusetts Ave NW, Washington, DC, 20036 (benedic.ippolito@aei.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.5440?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101025

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks